Skip to main content

Table 1 Differential expressed circulating microRNAs of ovarian cancer in profiling studies

From: Circulating MicroRNAs in gynecological malignancies: from detection to prediction

Dysregulated microRNAs Associations Histology Sources Methods References
Up-regulated Down-regulated
miR-21, 29a, 92, 93, 126 miR-127, 155, 99b   ovarian cancer serum, patient vs. normal control microarray,qRT-PCR Resnick, 2009 [14]
95 miRNAs 88 miRNAs, 4 validated by qRT-PCR: miR-132, 26a, let-7b, miR-145   serous ovarian cancer serum, patient vs. healthy control microarray,qRT-PCR Chung, 2013 [15]
miR-205, 643, 200a, 184, 9, 21*, let-7f-2*, miR-483-5p, 616*, 34a*, 501-5p, 141 let-7a, 7d*, 7e*, 106b*, 149, 193b*, 362-3p, 363*, 422a, 449a, 770-5p, 98, 15b*, let-7f, miR-221, 450a, 570, 573 lower let-7f vs. poor prognosis epithelial ovarian cancer plasma, patient vs. healthy control TaqMan Low Density Array, qRT-PCR Zheng, 2013 [18]
miR-1274a, 30b, 30c, 625-3p, 720;   serous epithelial ovarian cancer plasma, OC# patient vs. healthy volunteer TaqMan Open Array  
miR-106b, 126, 150, 17, 20a, 92a;   plasma, OC# patient vs. benign neoplasm Shapira, 2014 [16]
MiR-139-5p, 142-3p, 484, 486, 660   benign neoplasm vs. healthy volunteer
miR-21, 191, 16, 15b, 1977, 1979, 1973, 1974, 4284, 195;   EAOC##: endometrioidand/or clear cell adenocarcinoma plasma, EAOC patients vs. healthy controls RT-qPCR Suryawanshi, 2013 [17]
miR-362-5p, 1274a, 21, 766, 1975, 1308, 191, 744, 376a, 1246;   plasma, EAOC patients vs. endometriosis patients
miR-16, 195, 191, 1974, 4284, 15b, 1978, 1979, 362-5p, 1973   endometriosis patients vs. healthy controls
  1. #OC: ovarian cancer, ##EAOC: endometriosis-associated ovarian cancer.